Ads
related to: pediatric rheumatoid arthritis treatmentdoconsumer.com has been visited by 100K+ users in the past month
Search results
Results from the WOW.Com Content Network
Childhood arthritis (juvenile arthritis or pediatric rheumatic disease) is an umbrella term used to describe any rheumatic disease or chronic arthritis-related condition which affects individuals under the age of 16. There are several subtypes that differentiate themselves via prognosis, complications, and treatments.
Juvenile idiopathic arthritis (JIA), formerly known as juvenile rheumatoid arthritis (JRA), [1] is the most common chronic rheumatic disease of childhood, affecting approximately 3.8 to 400 out of 100,000 children. [3]
According to estimates, juvenile idiopathic arthritis (JIA) affects 1 to 4 out of every 1000 children, making it the most prevalent rheumatic illness in children. [ 34 ] [ 35 ] With incidence rates ranging from 0.4 to 0.8 children per 100,000 children, sJIA accounts for 10% to 20% of JIA cases.
The European Rheumatoid Arthritis Surgical Society (ERASS) was founded in 1979. [17] Around the turn of the 21st century, focus for treatment of patients with rheumatic disease shifted, and pharmacological treatment became dominant, while surgical interventions became rarer. [18] [19]
As of 2020, about 17.6 million people globally were living with rheumatoid arthritis, an autoimmune disease causing painful inflammation and swelling in joints.
Tocilizumab, sold under the brand name Actemra among others, is an immunosuppressive drug, used for the treatment of rheumatoid arthritis, systemic juvenile idiopathic arthritis, polyarticular juvenile idiopathic arthritis, giant cell arteritis, cytokine release syndrome, COVID‑19, and systemic sclerosis-associated interstitial lung disease (SSc-ILD).
Ads
related to: pediatric rheumatoid arthritis treatmentdoconsumer.com has been visited by 100K+ users in the past month